Tyrphostin AG-490 inhibited the acute phase of zymosan-induced inflammation

International Immunopharmacology

Volumn 8, Issue 11, 2008, Pages 1567-1577

  Dimitrova, Petya ^a   Ivanovska, Nina ^a  

^a INSTITUTE OF MICROBIOLOGY   (Bulgaria)

Author keywords

Cytokines; iNOS; Stat1; Stat3; Tyrphostin AG 490; Zymosan inflammation

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NITRIC OXIDE; STAT1 PROTEIN; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; ZYMOSAN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD CLOTTING TIME; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOKINE PRODUCTION; DRUG DOSE COMPARISON; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; INFLAMMATION; KIDNEY FAILURE; KIDNEY MASS; LIVER DYSFUNCTION; LIVER WEIGHT; LUNG WEIGHT; MALE; MOUSE; MULTIPLE ORGAN FAILURE; NONHUMAN; PERITONEUM LAVAGE; PRIORITY JOURNAL; SPLEEN WEIGHT;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; CREATININE; INFLAMMATION; INTERLEUKIN-6; MACROPHAGES; MALE; MICE; MULTIPLE ORGAN FAILURE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PROTEIN KINASE INHIBITORS; STAT TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR-ALPHA; TYRPHOSTINS; WHOLE BLOOD COAGULATION TIME; ZYMOSAN;

EID: 51749093698     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2008.06.013     Document Type: Article

References (47)

1. Goris R.J., Boekholtz W.K., van Bebber I.P., Nuytinck J.K., and Schillings P.H. Multiple-organ failure and sepsis without bacteria. An experimental model. Arch Surg 121 (1986) 897-901
2. Abraham E., and Singer M. Mechanisms of sepsis-induced organ dysfunction. Crit Care Med 35 (2007) 2408-2416
3. Cuzzocrea S., de Sarro G., Costantino G., Mazzon E., Laura R., Ciriaco E., et al. Role of interleukin-6 in a non-septic shock model induced by zymosan. Eur Cytokine Netw 10 (1999) 191-203
4. Malleo G., Mazzon E., Siriwardena A.K., and Cuzzocrea S. Role of tumor necrosis factor-alpha in acute pancreatitis: from biological basis to clinical evidence. Shock 28 (2007) 130-140
5. Miller C.G., Cook D.N., and Kotwal G.J. Two chemotactic factors, C5a and MIP-1alpha, dramatically alter the mortality from zymosan-induced multiple organ dysfunction syndrome (MODS): C5a contributes to MODS while MIP-1alpha has a protective role. Mol Immunol 33 (1996) 1135-1137
6. Philippart F., and Cavaillon J.M. Sepsis mediators. Curr Infect Dis Rep 9 (2007) 358-365
7. Burdon D., Tiedje T., Pfeffer K., Vollmer E., and Zabel P. The role of tumor necrosis factor in the development of multiple organ failure in a murine model. Crit Care Med 28 (2000) 1962-1967
8. Jansen M.J., Hendriks T., Vogels M.T., van der Meer J.W., and Goris R.J. Inflammatory cytokines in an experimental model for the multiple organ dysfunction syndrome. Crit Care Med 24 (1996) 1196-1202
9. Volman T.J., Hendriks T., Verhofstad A.A., Kullberg B.J., and Goris R.J. Improved survival of TNF-deficient mice during the zymosan-induced multiple organ dysfunction syndrome. Shock 17 (2002) 468-472
10. Jansen M.J., Henodriks T., Hermsen R., Van der Meer J.W., and Goris R.J. A monoclonal antibody against tumour necrosis factor-alpha improves survival in experimental multiple organ dysfunction syndrome. Cytokine 10 (1998) 904-910
11. Carrithers M., Tandon S., Canosa S., Michaud M., Graesser D., and Madri J.A. Enhanced susceptibility to endotoxic shock and impaired STAT3 signaling in CD31-deficient mice. Am J Pathol 166 (2005) 185-196
12. Cobb J.P. Nitric oxide synthase inhibition as therapy for sepsis: a decade of promise. Surg Infect (Larchmt) 2 (2001) 93-100 discussion-1
13. Volman T.J., Goris R.J., van der Jagt M., van de Loo F.A., and Hendriks T. Organ damage in zymosan-induced multiple organ dysfunction syndrome in mice is not mediated by inducible nitric oxide synthase. Crit Care Med 30 (2002) 1553-1559
14. Bromberg J., and Darnell Jr. J.E. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19 (2000) 2468-2473
15. Durbin J.E., Hackenmiller R., Simon M.C., and Levy D.E. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84 (1996) 443-450
16. Akira S. IL-6-regulated transcription factors. Int J Biochem Cell Biol 29 (1997) 1401-1418
17. Takeda K., Clausen B.E., Kaisho T., Tsujimura T., Terada N., Forster I., et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10 (1999) 39-49
18. Sareila O., Korhonen R., Karpanniemi O., Nieminen R., Kankaanranta H., and Moilanen E. JAK inhibitors AG-490 and WHI-P154 decrease IFN-gamma-induced iNOS expression and NO production in macrophages. Mediators Inflamm 2006 (2006) 16161
19. Garcia R., Bowman T.L., Niu G., Yu H., Minton S., Muro-Cacho C.A., et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20 (2001) 2499-2513
20. Dugo L., Chatterjee P.K., Mazzon E., McDonald M.C., Paola R.D., Fulia F., et al. The tyrosine kinase inhibitor tyrphostin AG 126 reduces the multiple organ failure induced by zymosan in the rat. Intensive Care Med 28 (2002) 775-788
21. Ogura S., Umegaki O., Genovese F., Fernando L.P., Cochran J.B., Romeo C.M., et al. Protective effect of tyrphostin AG-556 on shock induced by endotoxin or gram positive bacteria. Shock 12 (1999) 105-110
22. George J., Barshack I., Keren P., Gazit A., Levitzki A., Keren G., et al. The effect of tyrphostin AG-556 on intimal thickening in a mouse model of arterial injury. Exp Mol Pathol 78 (2005) 233-238
23. Ruetten H., and Thiemermann C. Effects of tyrphostins and genistein on the circulatory failure and organ dysfunction caused by endotoxin in the rat: a possible role for protein tyrosine kinase. Br J Pharmacol 122 (1997) 59-70
24. Marzocco S., Mazzon E., Pinto A., Autore G., and Cuzzocrea S. Tyrphostin AG 126 reduces intestinal ischemia-reperfusion injury in the rat. Naunyn Schmiedebergs Arch Pharmacol 372 (2006) 362-373
25. McDonald M., Abdelrahman M., Cuzzocrea S., and Thiemermann C. Tyrphostin reduces the organ injury in haemorrhagic shock: role of inducible nitric oxide synthase. Resuscitation 58 (2003) 349-361
26. Ivanovska N., Kalfin R., Lazarova M., and Dimitrova P. Exogenous VIP limits zymosan-induced generalized inflammation (ZIGI) in mice. Immunol Lett 110 (2007) 126-132
27. Xing L., and Remick D.G. Relative cytokine and cytokine inhibitor production by mononuclear cells and neutrophils. Shock 20 (2003) 10-16
28. Kuhn J.F., Godshall C.J., Scott M.J., Franklin G.A., Rowe S.A., Peyton J.C., et al. Immediate and delayed leukocyte apoptosis in two models of peritonitis. Inflammation 25 (2001) 389-397
29. Glauser M.P., Heumann D., Baumgartner J.D., and Cohen J. Pathogenesis and potential strategies for prevention and treatment of septic shock: an update. Clin Infect Dis 18 Suppl 2 (1994) S205-216
30. Bevilacqua M.P., Pober J.S., Majeau G.R., Fiers W., Cotran R.S., and Gimbrone Jr. M.A. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci U S A 83 (1986) 4533-4537
31. Szabo C., Hasko G., Nemeth Z.H., and Vizi E.S. Calcium entry blockers increase interleukin-10 production in endotoxemia. Shock 7 (1997) 304-307
32. Ivanovska N.D., Dimitrova P.A., Luckett J.C., El-Rachkidy Lonnen R., Schwaeble W.J., and Stover C.M. Properdin deficiency in murine models of nonseptic shock. J Immunol 180 (2008) 6962-6969
33. Leist M., Gantner F., Jilg S., and Wendel A. Activation of the 55 kDa TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis, and nitrite release. J Immunol 154 (1995) 1307-1316
34. Matsukawa A. STAT proteins in innate immunity during sepsis: lessons from gene knockout mice. Acta Med Okayama 61 (2007) 239-245
35. Yao Y.M., Wang S.B., Xian L.M., Zhai X.Z., Dong N., Yu Y., et al. The potential mechanism on signal transduction pathway in regulation of mRNA expression of high mobility group box-1 protein in septic rats. Zhonghua Wai Ke Za Zhi 44 (2006) 916-920
36. Kamezaki K., Shimoda K., Numata A., Matsuda T., Nakayama K., and Harada M. The role of Tyk2, Stat1 and Stat4 in LPS-induced endotoxin signals. Int Immunol 16 (2004) 1173-1179
37. Opal S.M., and DePalo V.A. Anti-inflammatory cytokines. Chest 117 (2000) 1162-1172
38. Matsukawa A., Takeda K., Kudo S., Maeda T., Kagayama M., and kira S. Aberrant inflammation and lethality to septic peritonitis in mice lacking STAT3 in macrophages and neutrophils. J Immunol 171 (2003) 6198-6205
39. George J., Barshack I., Goldberg I., Keren P., Gazit A., Levitzki A., et al. The effect of early and late treatment with the tyrphostin AG-556 on the progression of experimental autoimmune myocarditis. Exp Mol Pathol 76 (2004) 234-241
40. Balachandra S., Genovese T., Mazzon E., Di Paola R., Thiemerman C., Siriwardena A.K., et al. Inhibition of tyrosine-kinase-mediated cellular signaling by tyrphostins AG 126 and AG556 modulates murine experimental acute pancreatitis. Surgery 138 (2005) 913-923
41. Genovese T., Mazzon E., Esposito E., Muia C., Di Paola R., Crisafulli C., et al. Inhibition of tyrosine kinase-mediated cellular signalling by Tyrphostins AG126 and AG556 modulates secondary damage in experimental spinal cord trauma. Neuropharmacology 52 (2007) 1454-1471
42. Iwamaru A., Szymanski S., Iwado E., Aoki H., Yokoyama T., Fokt I., et al. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 26 (2007) 2435-2444
43. Matsukawa A., Kudo S., Maeda T., Numata K., Watanabe H., Takeda K., et al. Stat3 in resident macrophages as a repressor protein of inflammatory response. J Immunol 175 (2005) 3354-3359
44. Chung C.S., Song G.Y., Lomas J., Simms H.H., Chaudry I.H., and Ayala A. Inhibition of Fas/Fas ligand signaling improves septic survival: differential effects on macrophage apoptotic and functional capacity. J Leukoc Biol 74 (2003) 344-351
45. Chung C.S., Yang S., Song G.Y., Lomas J., Wang P., Simms H.H., et al. Inhibition of Fas signaling prevents hepatic injury and improves organ blood flow during sepsis. Surgery 130 (2001) 339-345
46. Li R., Yang N., Zhang L., Huang Y., Zhang R., Wang F., et al. Inhibition of Jak/STAT signaling ameliorates mice experimental nephrotic syndrome. Am J Nephrol 27 (2007) 580-589
47. Yang N., Luo M., Li R., Huang Y., Zhang R., Wu Q., et al. Blockage of JAK/STAT signalling attenuates renal ischaemia-reperfusion injury in rat. Nephrol Dial Transplant 23 (2008) 91-100